274 related articles for article (PubMed ID: 11439348)
1. Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Frasca F; Vigneri P; Vella V; Vigneri R; Wang JY
Oncogene; 2001 Jun; 20(29):3845-56. PubMed ID: 11439348
[TBL] [Abstract][Full Text] [Related]
2. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels.
Mineo R; Costantino A; Frasca F; Sciacca L; Russo S; Vigneri R; Belfiore A
Endocrinology; 2004 Sep; 145(9):4355-65. PubMed ID: 15192042
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
4. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
5. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Podtcheko A; Ohtsuru A; Tsuda S; Namba H; Saenko V; Nakashima M; Mitsutake N; Kanda S; Kurebayashi J; Yamashita S
J Clin Endocrinol Metab; 2003 Apr; 88(4):1889-96. PubMed ID: 12679488
[TBL] [Abstract][Full Text] [Related]
6. Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
Kawauchi K; Ogasawara T; Yasuyama M; Ohkawa Si
Blood Cells Mol Dis; 2003; 31(1):11-7. PubMed ID: 12850478
[TBL] [Abstract][Full Text] [Related]
7. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of the phosphoinositide 3-kinase and MAP kinase pathways by hepatocyte growth factor vs. insulin-like growth factor-I in myogenic cells.
Halevy O; Cantley LC
Exp Cell Res; 2004 Jul; 297(1):224-34. PubMed ID: 15194438
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
Deutsch E; Maggiorella L; Wen B; Bonnet ML; Khanfir K; Frascogna V; Turhan AG; Bourhis J
Br J Cancer; 2004 Nov; 91(9):1735-41. PubMed ID: 15494718
[TBL] [Abstract][Full Text] [Related]
10. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
11. Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity.
Qiao H; Saulnier R; Patryzkat A; Rahimi N; Raptis L; Rossiter J; Tremblay E; Elliott B
Cell Growth Differ; 2000 Feb; 11(2):123-33. PubMed ID: 10714768
[TBL] [Abstract][Full Text] [Related]
12. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
[TBL] [Abstract][Full Text] [Related]
13. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
14. Role of E2F and ERK1/2 in STI571-mediated smooth muscle cell growth arrest and cyclin A transcriptional repression.
Sanz-González SM; Castro C; Pérez P; Andrés V
Biochem Biophys Res Commun; 2004 May; 317(4):972-9. PubMed ID: 15094364
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
17. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
[TBL] [Abstract][Full Text] [Related]
19. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
[TBL] [Abstract][Full Text] [Related]
20. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]